Changes in clinical scenarios, management, and perspectives of patients with chronic hepatitis C after viral clearance by direct-acting antivirals.
Riccardo NevolaLuca RinaldiLetizia ZeniCiro RomanoAldo MarroneRaffaele GalieroPia Clara PafundiCarlo AciernoErica VetranoLuigi Elio AdinolfiPublished in: Expert review of gastroenterology & hepatology (2021)
Patients achieving HCV clearance have improved hepatic and extrahepatic diseases, quality of life and survival. They have lower incidence of cardiovascular disease, type 2 diabetes, kidney damage, and immuno-mediated manifestations. However, the improvements are related to the degree of pre-treatment organ damage. Therefore, a significant percentage of patients with advanced disease remains at risk of morbidity and mortality and must be monitored in the post-treatment. In addition, data emphasize the importance of starting treatment during the early stages of HCV infection.
Keyphrases
- type diabetes
- cardiovascular disease
- hepatitis c virus
- end stage renal disease
- oxidative stress
- chronic kidney disease
- ejection fraction
- sars cov
- climate change
- coronary artery disease
- metabolic syndrome
- prognostic factors
- newly diagnosed
- combination therapy
- big data
- skeletal muscle
- peritoneal dialysis
- glycemic control
- insulin resistance
- electronic health record
- replacement therapy